$14.99
0.886.24%
At close: -
$15.11
0.120.80%
After Hours: Dec 20, 5:39 PM EDT
Comments
Loading...
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock, Earnings Estimates, EPS, And Revenue
Arcutis Biotherapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 25
EPS Estimate
$-0.290
Quarterly Revenue Estimate
$54.7M
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$138.7M
Analyze the earnings history of Arcutis Biotherapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Arcutis Biotherapeutics (ARQT) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-06 | $-0.33 | $-0.42 | 21.4 % |
| Jun 2024 | 2024-08-14 | $-0.42 | $-0.57 | 26.3 % |
| Mar 2024 | 2024-05-14 | $-0.32 | $-0.73 | 56.2 % |
| Dec 2023 | 2024-02-27 | $-0.72 | $-0.77 | 6.49 % |
Arcutis Biotherapeutics (ARQT) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-06 | $44.76M | $37.62M | 19.0 % |
| Jun 2024 | 2024-08-14 | $30.86M | $27.12M | 13.8 % |
| Mar 2024 | 2024-05-14 | $49.57M | $14.68M | 237.7 % |
| Dec 2023 | 2024-02-27 | $13.53M | $11.34M | 19.3 % |
FAQ
When is Arcutis Biotherapeutics (NASDAQ:ARQT) reporting earnings?
Arcutis Biotherapeutics (ARQT) is scheduled to report earnings on February 25, 2025. The last reported earnings were for reported on November 6, 2024 for Q3.
What were the latest earnings per share (EPS) for Arcutis Biotherapeutics (NASDAQ:ARQT)?
The Actual EPS was $-0.33, which beat the estimate of $-0.42.
What were Arcutis Biotherapeutics’s (NASDAQ:ARQT) revenues?
The Actual Revenue was $44.8M, which beat the estimate of $37.6M.
Browse earnings estimates, EPS, and revenue on all stocks.